Prurigo nodularis

Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 11, 2023

NEW HAVEN, Conn., April 11, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that Jennifer Good, President and Chief Executive Officer, Lisa Delfini, Chief Financial Officer, and David Clark, MD, Chief Medical Officer, will be participating in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, at 11:00 a.m. ET. Ms. Good and Ms. Delfini will also participate in investor meetings with attendees.

Key Points: 
  • Fireside chat will be held on Monday, April 17, 2023, at 11:00 a.m.
  • Ms. Good and Ms. Delfini will also participate in investor meetings with attendees.
  • A live webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

AAD 2023: Late-Breaking Phase III Results Demonstrate nemolizumab’s Significant Impact on Prurigo Nodularis

Retrieved on: 
Saturday, March 18, 2023

Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.

Key Points: 
  • Galderma has an extensive presence at the meeting with further updates from its broad portfolio across Therapeutic Dermatology, Dermatological Skincare and Injectable Aesthetics.
  • The phase III OLYMPIA 2 trial met all primary endpoints, showing nemolizumab monotherapy significantly improved pruritus (itch) and skin lesions compared with placebo in adult patients with moderate to severe prurigo nodularis.
  • “We are so pleased that we’re able to bring so much powerful new data to this year’s AAD congress.
  • Its continued commitment to delivering science and innovation across a highly differentiated portfolio is reflected in its extensive presence at AAD.

Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023

Retrieved on: 
Thursday, March 9, 2023

NEW HAVEN, Conn., March 9, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, March 16, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • ET, to provide a corporate update and review the Company's financial results for the fourth quarter and full year ended December 31, 2022.
  • To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 1366506.
  • A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

Trevi Therapeutics to Participate in Upcoming March Conferences

Retrieved on: 
Monday, March 6, 2023

NEW HAVEN, Conn., March 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior management will attend and participate in the following March conferences.

Key Points: 
  • Oppenheimer 33rd Annual Healthcare Conference, March 13-15 – Corporate presentation will be held on Monday, March 13, at 4:00 p.m.
  • ET
    NEW HAVEN, Conn., March 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior management will attend and participate in the following March conferences.
  • Oppenheimer 33rd Annual Healthcare Conference (March 13-15, 2023)
    Presentation Date/Time: Monday, March 13 at 4:00 p.m.
  • ET
    Dates: March 20-22, 2023 (in-person) and March 28-30, 2023 (virtual)
    For more information or to register, please click here .

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023

HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
  • Celldex believes her deep background in drug development strongly complements the current Board’s skills and experiences.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • The litigation settlement related loss had a ($0.32) impact on net loss per share for the twelve months ended December 31, 2022.

Trevi Therapeutics to Present and Participate in Upcoming February Conferences

Retrieved on: 
Thursday, February 2, 2023

NEW HAVEN, Conn., Feb. 2, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior leadership will attend and present at the following February investor conferences.

Key Points: 
  • ET
    SVB Securities Global Biopharma Conference, February 13-16 – Corporate presentation Tuesday, February 14, at 11:20 a.m.
  • ET
    SVB Securities Global Biopharma Conference (February 13-16, 2023)
    Presentation Date/Time: Tuesday, February 14 at 11:20 a.m.
  • ET
    A live webcast of the SVB Securities Global Biopharma Conference corporate presentation will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com .
  • An archived replay of the audio webcast will also be available on the Company's website following the event.

Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast

Retrieved on: 
Wednesday, January 25, 2023

President and CEO of the Company, Jennifer Good, joined Stock Day host Everett Jolly.

Key Points: 
  • President and CEO of the Company, Jennifer Good, joined Stock Day host Everett Jolly.
  • "Our path forward here is through severe chronic cough, which is also linked to some tough diseases."
  • Jolly then asked for an update on the Company's Phase 2 CANAL trial of its investigational oral therapy Haduvio™ in chronic cough in IPF.
  • She also encouraged listeners and shareholders to keep up-to-date on the Company's upcoming announcements and current projects as they continue to progress clinically.

Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference

Retrieved on: 
Monday, December 19, 2022

NEW HAVEN, Conn., Dec. 19, 2022  /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior leadership will attend and present at the following investor and partnership conferences in January. These events will take place in San Francisco during the week of the annual J.P. Morgan Health Care Conference.

Key Points: 
  • These events will take place in San Francisco during the week of the annual J.P. Morgan Health Care Conference.
  • Biotech Showcase 2023 (January 9-11, 2023)
    For more information or to register, please click here .
  • Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).
  • The ĸ- and µ-opioid receptors are centrally and peripherally active and known to be critical mediators of cough and itch.

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Retrieved on: 
Monday, November 14, 2022

NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.

Key Points: 
  • Most recently, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, leading the Company's clinical development, regulatory and medical affairs teams.
  • Prior to that, he served as Chief Medical Officer for various companies, including Aldeyra Therapeutics, Wilson Therapeutics, and NormOxys.
  • As Chief Medical Officer, Dr. Clark has strategized and supported teams from clinical translation through Phase 3.
  • Dr. Thomas Sciascia, MD, the co-founder of Trevi Therapeutics, previously served as Trevi's Chief Medical Officer and will be transitioning to Chief Science Officer.

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022

HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Barzolvolimab is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity.
  • Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2022 were $323.5 million compared to $356.8 million as of June 30, 2022.
  • Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.